ugichem is developing next generation antisense drugs, called Ugimers. The “Ugimer toolkit” allows an unattainable customization of cell and organ specificity for antisense drugs to target previously inaccessible clinical pathways.
-
Recent Posts
- EU-Backed SHOP4CF Announces Open Call For 4th Industrial Revolution Startups
- Founder Institute introduces new cohort in Finland for early-stage food tech entrepreneurs
- Shwetak Patel to highlight new approaches to healthcare and mobile
- Founder Institute CEO Adeo Ressi to run webinar offering COVID-19 startup survival tips
